Autotaxin inhibitors: a patent review (2012-2016). (3rd July 2017)

• Record Type: Journal Article
• Authors: Nikolaou, Aikaterini; Kokotou, Maroula G.; Limnios, Dimitris; Psarra, Anastasia; Kokotos, George
• Is Part Of: Expert opinion on therapeutic patents. Volume 27:Number 7(2017:Jul.)
• Page Start: 815
• Page End: 829
• Publication Date: 2017-07-03
• Subjects: Autotaxin -- cancer -- inflammation -- inhibitors -- lysophosphatidic acid; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2017.1323331
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : Autotaxin (ATX) is a secreted enzyme that hydrolyzes lysophosphatidylcholine to lysophosphatidic acid (LPA) and choline. The ATX/LPA axis has received increasing interest in recent years because both the enzyme ATX and the bioactive lipid LPA are involved in various pathological conditions such as tumor progression and metastasis, fibrotic diseases, autoimmune diseases, arthritis, chronic hepatitis, obesity and impaired glucose homeostasis. Thus, a great effort has been devotd in developing synthetic ATX inhibitors as new agents to treat various diseases including cancer and fibrotic diseases. Areas covered : This review article summarizes the autotaxin inhibitors presented in patent literature from October 2012 to August 2016 and their biological evaluation, discussing their activities in vitro and in vivo . Expert opinion : During the recent years, there has been an intensive effort on the discovery of potent and selective ATX inhibitors. Although various synthetic inhibitors have been developed, only limited studies for their in vivo activity have been reported so far. A decade after the first claim of synthetic ATX inhibitors in 2006, one inhibitor has been in clinical trials for idiopapthic pulmonary fibrosis. The use of ATX inhibitors seems an attractive strategy to produce novel medicinal agents, for example anticancer agents.